Adding interferon-α to octreotide slows tumour progression compared with octreotide alone but evidence is lacking for improved survival in people with disseminated midgut carcinoid tumours: Abstracted from: Kölby L, Persson G, Franzén S, Ahrén B, Randomized clinical trial of the effect of interferon-α on survival in patients with disseminated midgut carcinoid tumours. British Journal of Surgery 2003; 90: 687–693.